Werfen increases sales by over 13% and reaffirms its global leadership in in vitro diagnostics

Food and Healthcare Press Releases Friday April 27, 2018 13:44
BARCELONA, Spain--27 Apr--PRNewswire/InfoQuest
Werfen, a global leader in healthcare and life sciences, achieves revenues of 1,337 million euros in 2017, a 13.3% increase against 2016.

Excluding the impact of recent acquisitions, sales from organic growth grew by 4.6%. With these results, Werfen continues to be a global leader in in vitro diagnostics, providing innovative solutions for hospitals and commercial laboratories with the aim of improving patient care and reducing healthcare costs.

Werfen is reporting net profit of 160 million euros for 2017, representing a 15.1% increase over 2016. EBITDA has grown to 284 million euros, representing an increase of 6%.

Werfen is performing very well in its main areas of expertise. Hemostasis has an increase of 7.5%, Autoimmunity has grown by 6.6%, while the new business line, Acute Care Diagnostics, has achieved organic growth of 4.8%.

The expansion of the product portfolio has been one of the main causes of the increase in sales following the acquisitions of Tem and Accriva Diagnostics. As a result, the Critical Care business line has evolved into Acute Care Diagnostics, providing comprehensive solutions for emergency care, traumatology, and operating rooms.

Werfen has strengthened its presence in all regions, especially in China, where sales have achieved a 21% increase against 2016. Currently, Asia-Pacific accounts for 16% of total revenues.

Western Europe is the strongest market, bringing in 42% of Werfen revenues, while North America accounted for 26%. The areas with the greatest potential for growth are Latin America and EEMEAI (Eastern Europe, Middle East, Africa and India), each of which generated 8% of total sales.

The objectives set for 2018 are to further strengthen the main areas of expertise, to continue to grow in China, and to boost expansion in the emerging markets of Latin America, Asia-Pacific and EEMEAI.

WERFEN is one of the leading global corporations in IVD through its companies Instrumentation Laboratory (Hemostasis, Acute Care Diagnostics), Inova Diagnostics (Autoimmunity) and Biokit (OEM, infectious disease serology); in addition to clinical software and chemical chemistry. Werfen is also involved in medical devices through its company Leventon and other entities for distribution.

Werfen has a direct presence in around 30 countries and more than 100 territories through distributors. It has a team of over 5,000 people, and its R&D and manufacturing activities are carried out in the United States and Europe.


Latest Press Release

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

5 Ways to Set Healthy Grocery Shopping Habits in 2019

By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center first in U.S. to treat patient in study to evaluate balloon ablation catheter for treating Atrial Fibrillation

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently performed the first procedure in the U.S. using the new HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter as part of the STELLAR study. The study...

FDA Accepts sBLA and Grants Priority Review for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*...

BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),...

Related Topics